OrthoPediatrics (KIDS) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

KIDS Stock Forecast


OrthoPediatrics stock forecast is as follows: an average price target of $39.50 (represents a 76.50% upside from KIDS’s last price of $22.38) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

KIDS Price Target


The average price target for OrthoPediatrics (KIDS) is $39.50 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $44.00 to $28.00. This represents a potential 76.50% upside from KIDS's last price of $22.38.

KIDS Analyst Ratings


Buy

According to 7 Wall Street analysts, OrthoPediatrics's rating consensus is 'Buy'. The analyst rating breakdown for KIDS stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

OrthoPediatrics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 14, 2024Richard NewitterTruist Financial$28.00$25.579.50%25.11%
Sep 13, 2024Mike MatsonNeedham$42.00$31.6032.91%87.67%
Sep 13, 2024Kaila KrumTruist Financial$34.00$31.607.59%51.92%
Sep 06, 2024Matt O'BrienPiper Sandler$44.00$29.8847.26%96.60%
Sep 06, 2024Ryan ZimmermanBTIG$44.00$29.8847.26%96.60%
Jul 16, 2024Richard NewitterTruist Financial$35.00$34.441.63%56.39%
May 07, 2024Rick WiseStifel Nicolaus$40.00$34.7015.27%78.73%
Aug 05, 2022Truist Financial$66.00$55.0619.87%194.91%
Jul 18, 2022BTIG$61.00$42.9941.89%172.56%
Jul 18, 2022Stifel Nicolaus$50.00$42.9916.31%123.41%
May 05, 2022Needham$59.00$44.1333.70%163.63%

The latest OrthoPediatrics stock forecast, released on Oct 14, 2024 by Richard Newitter from Truist Financial, set a price target of $28.00, which represents a 9.50% increase from the stock price at the time of the forecast ($25.57), and a 25.11% increase from KIDS last price ($22.38).

OrthoPediatrics Price Target by Period


1M3M12M
# Anlaysts-17
Avg Price Target-$28.00$38.14
Last Closing Price$22.38$22.38$22.38
Upside/Downside-100.00%25.11%70.42%

In the current month, the average price target of OrthoPediatrics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to OrthoPediatrics's last price of $22.38. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Sep 13, 2024Truist FinancialBuyBuyHold
Sep 13, 2024NeedhamBuyBuyHold
Sep 06, 2024Piper SandlerOverweightOverweightHold
Sep 06, 2024BTIGBuyBuyHold
May 07, 2024NeedhamMarket OutperformMarket OutperformHold
Mar 07, 2024Truist FinancialMarket OutperformMarket OutperformHold
Oct 04, 2023BernsteinOutperformOutperformHold
Oct 04, 2023BTIGBuyBuyHold
Oct 04, 2023BarclaysBuyBuyHold
Jan 10, 2023NeedhamBuyBuyHold
Nov 01, 2022Piper SandlerOverweightOverweightHold
Oct 18, 2022GuggenheimBuyBuyHold
Jul 18, 2022BTIGBuyBuyHold

OrthoPediatrics's last stock rating was published by Truist Financial on Sep 13, 2024. The company gave KIDS a "Buy" rating, the same as its previous rate.

OrthoPediatrics Financial Forecast


OrthoPediatrics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$37.61M$39.97M$39.56M$31.59M$30.99M$34.95M$32.93M$23.42M$24.81M$25.08M$26.70M$21.46M$18.92M$22.20M$13.59M$16.36M$18.95M$20.74M
Avg Forecast$68.42M$74.24M$71.84M$60.46M$60.24M$64.44M$62.28M$52.73M$50.72M$53.73M$52.52M$41.78M$37.73M$40.37M$39.13M$29.31M$31.00M$36.15M$32.40M$22.76M$24.71M$26.28M$24.25M$19.90M$20.32M$19.97M$11.43M$17.04M$18.34M$19.87M
High Forecast$69.10M$74.98M$72.55M$61.06M$60.83M$65.07M$62.90M$52.75M$50.85M$53.75M$52.52M$42.06M$37.74M$40.37M$39.52M$29.60M$31.31M$36.15M$32.40M$22.76M$24.71M$26.28M$24.25M$19.90M$20.32M$19.97M$11.43M$17.04M$18.34M$19.87M
Low Forecast$68.07M$73.86M$71.47M$60.15M$59.92M$64.10M$61.96M$52.71M$50.63M$53.71M$52.52M$41.50M$37.72M$40.37M$38.93M$29.16M$30.84M$36.15M$32.40M$22.76M$24.71M$26.28M$24.25M$19.90M$20.32M$19.97M$11.43M$17.04M$18.34M$19.87M
# Analysts1111111342224222111122221016811711
Surprise %------------1.00%0.99%1.01%1.08%1.00%0.97%1.02%1.03%1.00%0.95%1.10%1.08%0.93%1.11%1.19%0.96%1.03%1.04%

OrthoPediatrics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $41.78M, with a low forecast of $41.50M, and a high forecast of $42.06M. KIDS's average Quarter revenue forecast represents a 11.08% increase compared to the company's last Quarter revenue of $37.61M (Dec 23).

OrthoPediatrics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts1111111342224222111122221016811711
EBITDA------------$-8.07M$-3.52M$-1.22M$-5.41M$-4.92M$-1.01M$-4.57M$-3.32M$3.04M$776.00K$-853.00K$-7.42M$-11.80M$-1.12M$-6.14M$-3.19M$-2.71M$-21.00K
Avg Forecast$-7.82M$-8.48M$-8.21M$-6.91M$-6.88M$-7.36M$-7.11M$-6.02M$-5.79M$-6.14M$-6.00M$-4.77M$-4.31M$-4.61M$-4.47M$-3.35M$-3.54M$-3.18M$-2.85M$-6.46M$-2.18M$-2.31M$-2.14M$-8.17M$-1.79M$-1.76M$-1.01M$-2.55M$-1.62M$-1.75M
High Forecast$-7.78M$-8.44M$-8.16M$-6.87M$-6.85M$-7.32M$-7.08M$-6.02M$-5.78M$-6.14M$-6.00M$-4.74M$-4.31M$-4.61M$-4.45M$-3.33M$-3.52M$-3.18M$-2.85M$-5.17M$-2.18M$-2.31M$-2.14M$-6.53M$-1.79M$-1.76M$-1.01M$-2.04M$-1.62M$-1.75M
Low Forecast$-7.89M$-8.56M$-8.29M$-6.98M$-6.95M$-7.43M$-7.19M$-6.03M$-5.81M$-6.14M$-6.00M$-4.80M$-4.31M$-4.61M$-4.51M$-3.38M$-3.58M$-3.18M$-2.85M$-7.75M$-2.18M$-2.31M$-2.14M$-9.80M$-1.79M$-1.76M$-1.01M$-3.06M$-1.62M$-1.75M
Surprise %------------1.87%0.76%0.27%1.62%1.39%0.32%1.60%0.51%-1.40%-0.34%0.40%0.91%6.59%0.64%6.10%1.25%1.68%0.01%

1 analysts predict KIDS's average Quarter EBITDA for Mar 22 to be $-6.46M, with a high of $-5.17M and a low of $-7.75M. This is -312.39% lower than OrthoPediatrics's previous annual EBITDA (Dec 21) of $3.04M.

OrthoPediatrics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts1111111342224222111122221016811711
Net Income------------$-6.69M$-4.59M$-2.89M$-6.81M$-7.85M$18.54M$-333.00K$-9.10M$72.00K$-2.20M$-3.76M$-10.38M$-14.01M$-4.54M$-9.45M$-4.95M$-5.43M$-2.66M
Avg Forecast$-5.02M$-3.38M$-2.98M$-8.39M$-6.28M$-3.69M$-3.75M$-8.54M$-6.91M$-5.25M$-6.09M$-9.38M$-6.22M$-4.94M$-4.75M$-8.16M$-5.31M$-4.03M$-4.36M$-6.64M$-7.12M$-6.44M$-7.44M$-11.42M$-6.33M$-7.08M$-8.83M$-3.96M$-5.79M$-4.05M
High Forecast$-4.99M$-3.36M$-2.96M$-8.34M$-6.24M$-3.67M$-3.73M$-8.48M$-6.28M$-5.22M$-6.05M$-9.31M$-5.78M$-4.91M$-4.72M$-8.10M$-5.27M$-4.03M$-4.36M$-5.31M$-7.12M$-6.44M$-7.44M$-9.13M$-6.33M$-7.08M$-8.83M$-3.16M$-5.79M$-4.05M
Low Forecast$-5.09M$-3.43M$-3.02M$-8.50M$-6.36M$-3.74M$-3.80M$-8.65M$-7.23M$-5.32M$-6.17M$-9.50M$-6.44M$-5.01M$-4.81M$-8.26M$-5.37M$-4.03M$-4.36M$-7.97M$-7.12M$-6.44M$-7.44M$-13.70M$-6.33M$-7.08M$-8.83M$-4.75M$-5.79M$-4.05M
Surprise %------------1.08%0.93%0.61%0.83%1.48%-4.60%0.08%1.37%-0.01%0.34%0.50%0.91%2.21%0.64%1.07%1.25%0.94%0.66%

OrthoPediatrics's average Quarter net income forecast for Dec 22 is $-5.31M, with a range of $-5.37M to $-5.27M. KIDS's average Quarter net income forecast represents a -128.62% decrease compared to the company's last Quarter net income of $18.54M (Sep 22).

OrthoPediatrics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts1111111342224222111122221016811711
SG&A------------$32.03M$32.09M$32.82M$29.88M$27.50M$27.04M$26.98M$22.93M$22.03M$20.90M$21.96M$20.99M$19.47M$19.06M$16.20M$15.45M$15.58M$16.04M
Avg Forecast$59.76M$64.84M$62.74M$52.81M$52.61M$56.28M$54.40M$46.05M$44.30M$46.93M$45.88M$36.49M$32.95M$35.26M$34.18M$25.60M$27.08M$30.73M$27.54M$16.73M$21.00M$22.34M$20.62M$16.91M$17.27M$16.97M$9.72M$12.36M$15.59M$16.89M
High Forecast$60.35M$65.49M$63.37M$53.33M$53.13M$56.84M$54.94M$46.07M$44.41M$46.94M$45.88M$36.74M$32.96M$35.26M$34.52M$25.85M$27.34M$30.73M$27.54M$20.07M$21.00M$22.34M$20.62M$16.91M$17.27M$16.97M$9.72M$14.83M$15.59M$16.89M
Low Forecast$59.45M$64.51M$62.42M$52.54M$52.34M$55.99M$54.12M$46.03M$44.22M$46.91M$45.88M$36.25M$32.94M$35.26M$34.00M$25.47M$26.94M$30.73M$27.54M$13.38M$21.00M$22.34M$20.62M$16.91M$17.27M$16.97M$9.72M$9.88M$15.59M$16.89M
Surprise %------------0.97%0.91%0.96%1.17%1.02%0.88%0.98%1.37%1.05%0.94%1.07%1.24%1.13%1.12%1.67%1.25%1.00%0.95%

OrthoPediatrics's average Quarter SG&A projection for Mar 24 is $36.49M, based on 2 Wall Street analysts, with a range of $36.25M to $36.74M. The forecast indicates a 13.92% rise compared to KIDS last annual SG&A of $32.03M (Dec 23).

OrthoPediatrics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts1111111342224222111122221016811711
EPS------------$-0.00$-0.20$-0.13$-0.30$-0.35$0.88$-0.02$-0.47-$-0.11$-0.19$-0.54$-0.73$-0.24$-0.54$-0.30$-0.36$-0.18
Avg Forecast$-0.22$-0.15$-0.13$-0.36$-0.27$-0.16$-0.16$-0.37$-0.30$-0.23$-0.26$-0.40$-0.27$-0.21$-0.20$-0.35$-0.23$-0.17$-0.19$-0.35$-0.31$-0.28$-0.32$-0.27$-0.27$-0.31$-0.38$-0.25$-0.25$-0.17
High Forecast$-0.22$-0.14$-0.13$-0.36$-0.27$-0.16$-0.16$-0.37$-0.27$-0.23$-0.26$-0.40$-0.25$-0.21$-0.20$-0.35$-0.23$-0.17$-0.19$-0.35$-0.31$-0.28$-0.32$-0.27$-0.27$-0.31$-0.38$-0.25$-0.25$-0.17
Low Forecast$-0.22$-0.15$-0.13$-0.37$-0.27$-0.16$-0.16$-0.37$-0.31$-0.23$-0.27$-0.41$-0.28$-0.22$-0.21$-0.36$-0.23$-0.17$-0.19$-0.35$-0.31$-0.28$-0.32$-0.27$-0.27$-0.31$-0.38$-0.25$-0.25$-0.17
Surprise %------------0.00%0.94%0.63%0.85%1.53%-5.06%0.09%1.33%-0.01%0.40%0.59%2.03%2.67%0.78%1.42%1.18%1.44%1.03%

According to 1 Wall Street analysts, OrthoPediatrics's projected average Quarter EPS for Dec 22 is $-0.23, with a low estimate of $-0.23 and a high estimate of $-0.23. This represents a -126.02% decrease compared to KIDS previous annual EPS of $0.88 (Sep 22).

OrthoPediatrics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
LUNGPulmonx$6.13$13.00112.07%Buy
SGHTSight Sciences$3.62$7.50107.18%Hold
KIDSOrthoPediatrics$22.46$39.5075.87%Buy
LIVNLivaNova$49.94$68.2536.66%Buy
CNMDCONMED$71.23$97.0036.18%Buy
OFIXOrthofix Medical$17.93$24.0033.85%
SIBNSI-BONE$13.84$18.5033.67%Buy
NPCENeuroPace$11.52$15.0030.21%Buy
IRTCiRhythm$91.45$111.3821.79%Buy
FNAParagon 28$10.36$11.5011.00%Buy
CVRXCVRx$13.16$14.258.28%Buy
SRDXSurmodics$39.96$39.50-1.15%Buy
GKOSGlaukos$146.35$144.14-1.51%Buy

KIDS Forecast FAQ


Is OrthoPediatrics a good buy?

Yes, according to 7 Wall Street analysts, OrthoPediatrics (KIDS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of KIDS's total ratings.

What is KIDS's price target?

OrthoPediatrics (KIDS) average price target is $39.5 with a range of $28 to $44, implying a 76.50% from its last price of $22.38. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will OrthoPediatrics stock go up soon?

According to Wall Street analysts' prediction for KIDS stock, the company can go up by 76.50% (from the last price of $22.38 to the average price target of $39.5), up by 96.60% based on the highest stock price target, and up by 25.11% based on the lowest stock price target.

Can OrthoPediatrics stock reach $30?

KIDS's average twelve months analyst stock price target of $39.5 supports the claim that OrthoPediatrics can reach $30 in the near future.

What are OrthoPediatrics's analysts' financial forecasts?

OrthoPediatrics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $239.68M (high $241.55M, low $238.69M), average EBITDA is $-27.379M (high $-27.266M, low $-27.593M), average net income is $-22.266M (high $-22.116M, low $-22.553M), average SG&A $209.34M (high $210.97M, low $208.48M), and average EPS is $-0.961 (high $-0.954, low $-0.973). KIDS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $274.97M (high $277.69M, low $273.54M), average EBITDA is $-31.41M (high $-31.247M, low $-31.721M), average net income is $-19.778M (high $-19.645M, low $-20.033M), average SG&A $240.16M (high $242.54M, low $238.92M), and average EPS is $-0.854 (high $-0.848, low $-0.865).

Did the KIDS's actual financial results beat the analysts' financial forecasts?

Based on OrthoPediatrics's last annual report (Dec 2023), the company's revenue was $148.73M, beating the average analysts forecast of $146.54M by 1.49%. Apple's EBITDA was $-25.766M, beating the average prediction of $-16.74M by 53.92%. The company's net income was $-20.974M, missing the average estimation of $-24.071M by -12.87%. Apple's SG&A was $126.82M, missing the average forecast of $127.99M by -0.91%. Lastly, the company's EPS was $-0.0009, missing the average prediction of $-1.039 by -99.91%. In terms of the last quarterly report (Dec 2023), OrthoPediatrics's revenue was $37.61M, missing the average analysts' forecast of $37.73M by -0.31%. The company's EBITDA was $-8.066M, beating the average prediction of $-4.31M by 87.16%. OrthoPediatrics's net income was $-6.691M, beating the average estimation of $-6.222M by 7.53%. The company's SG&A was $32.03M, missing the average forecast of $32.95M by -2.79%. Lastly, the company's EPS was $-0.0003, missing the average prediction of $-0.269 by -99.89%